Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMA vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Acute musculoskeletal pain (FDA-approved),Off-label: chronic low back pain, muscle spasms associated with neurological disorders
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
250 mg to 350 mg orally three times daily and at bedtime.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
1-2 hours; prolonged to 3-4 hours in hepatic impairment; parent drug rapidly cleared via CYP2C19 metabolism to meprobamate (active, t1/2 6-16 hours).
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Hepatic via CYP2C19 and CYP3A4; also undergoes dealkylation and hydroxylation.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Renal: ~60-70% as metabolites (including meprobamate and glucuronide conjugates); fecal: minimal; biliary: negligible.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
~60% bound to albumin.
30-35% bound to albumin.
0.7-1.0 L/kg; consistent with moderate tissue distribution.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: ~100% (rapidly and completely absorbed).
Oral: 70-85% with high variability; intrathecal: 100%.
No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 m L/min).
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in mild to moderate impairment; reduce dose or extend dosing interval.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Not recommended for children under 12 years of age. For adolescents, adult dosing may be considered based on weight and clinical judgment.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Initiate at lower doses (e.g., 250 mg three times daily) due to increased sensitivity and risk of CNS adverse effects; monitor renal function.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
None
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
May cause sedation, dizziness, and impaired psychomotor function; avoid driving or operating machinery.,Risk of abuse, dependence, and withdrawal; use with caution in patients with substance use disorder.,Concomitant use with alcohol or other CNS depressants may potentiate effects.,Elderly patients more sensitive to anticholinergic effects; monitor for confusion or falls.,Hepatic impairment: reduce dose or avoid use.,Pregnancy: limited data; use only if clearly needed.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to carisoprodol or its components,Acute intermittent porphyria,Concurrent use with other CNS depressants (relative)
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
No specific food interactions reported. Avoid alcohol and grapefruit juice as they may enhance sedative effects.
No specific food interactions. Avoid alcohol due to additive CNS depression.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, hypertonia) with chronic maternal use near term.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
M/P ratio unknown. Carisoprodol and its active metabolite meprobamate are excreted in breast milk. Potential for sedation in nursing infants. Use caution; monitor infant for drowsiness and feeding difficulties.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
No pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration; avoid chronic use due to risk of dependence and neonatal withdrawal.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
SOMA (carisoprodol) is a centrally acting skeletal muscle relaxant metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with porphyria. Use lowest effective dose for shortest duration (max 2-3 weeks). Monitor for sedation and dizziness, especially when combined with other CNS depressants. Taper to avoid withdrawal if used long-term.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Avoid driving or operating machinery until you know how SOMA affects you, as it may cause drowsiness or dizziness.,Do not consume alcohol or other CNS depressants (e.g., benzodiazepines, opioids) while taking SOMA.,Take exactly as prescribed; do not increase dose or duration due to risk of dependence and withdrawal.,Store securely to prevent misuse; dispose of unused medication properly.,Contact your doctor if you experience severe drowsiness, confusion, or signs of allergic reaction.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
"Somatostatin, a potent inhibitor of growth hormone and insulin secretion, may antagonize the effects of methohexital, a barbiturate anesthetic, by altering glucose metabolism and hemodynamic stability. This interaction can lead to reduced efficacy of methohexital, requiring higher doses for induction of anesthesia, and may increase the risk of prolonged recovery or adverse cardiovascular events. Clinically, patients may experience unpredictable depth of anesthesia or delayed emergence."
"Concurrent administration of somatostatin and pentobarbital may lead to enhanced CNS depression and increased risk of hypotension. Somatostatin inhibits the release of several hormones and can potentiate the sedative effects of pentobarbital through additive central nervous system depression. Clinically, this interaction may result in excessive sedation, respiratory depression, and cardiovascular instability, particularly in elderly or debilitated patients."
"Somatostatin inhibits the release of growth hormone and various gastrointestinal hormones, leading to reduced hepatic blood flow and decreased metabolic clearance of coadministered drugs. Thiopental undergoes extensive hepatic metabolism and its clearance may be impaired by somatostatin-induced reduction in hepatic perfusion, potentially resulting in prolonged anesthesia and increased risk of respiratory depression or hypotension. Additionally, somatostatin may directly enhance the central nervous system depressant effects of thiopental, although the clinical significance of this interaction is variable."
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMA vs BACLOFEN, answered by our medical review team.
SOMA is a Skeletal Muscle Relaxant that works by Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMA and BACLOFEN depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMA is: 250 mg to 350 mg orally three times daily and at bedtime.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMA and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMA is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third trimester: Risk of neonatal with. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.